These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33890576)

  • 1. Clinically Actionable Findings Derived From Predictive Genomic Testing Offered in a Medical Practice Setting.
    Anderson JL; Kruisselbrink TM; Lisi EC; Hughes TM; Steyermark JM; Winkler EM; Berg CM; Vierkant RA; Gupta R; Ali AH; Faubion SS; Aoudia SL; McAllister TM; Farrugia G; Stewart AK; Lazaridis KN
    Mayo Clin Proc; 2021 Jun; 96(6):1407-1417. PubMed ID: 33890576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of a Randomized Controlled Trial of Genomic Counseling for Patients Receiving Personalized and Actionable Complex Disease Reports.
    Sweet K; Sturm AC; Schmidlen T; McElroy J; Scheinfeldt L; Manickam K; Gordon ES; Hovick S; Scott Roberts J; Toland AE; Christman M
    J Genet Couns; 2017 Oct; 26(5):980-998. PubMed ID: 28345121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physician-directed genetic screening to evaluate personal risk for medically actionable disorders: a large multi-center cohort study.
    Haverfield EV; Esplin ED; Aguilar SJ; Hatchell KE; Ormond KE; Hanson-Kahn A; Atwal PS; Macklin-Mantia S; Hines S; Sak CW; Tucker S; Bleyl SB; Hulick PJ; Gordon OK; Velsher L; Gu JYJ; Weissman SM; Kruisselbrink T; Abel C; Kettles M; Slavotinek A; Mendelsohn BA; Green RC; Aradhya S; Nussbaum RL
    BMC Med; 2021 Aug; 19(1):199. PubMed ID: 34404389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1 in 38 individuals at risk of a dominant medically actionable disease.
    Haer-Wigman L; van der Schoot V; Feenstra I; Vulto-van Silfhout AT; Gilissen C; Brunner HG; Vissers LELM; Yntema HG
    Eur J Hum Genet; 2019 Feb; 27(2):325-330. PubMed ID: 30291343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Cancer Genetic Panel Testing on at-Risk Individuals.
    Frost AS; Toaff M; Biagi T; Stark E; McHenry A; Kaltman R
    Obstet Gynecol; 2018 Jun; 131(6):1103-1110. PubMed ID: 29742654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing for Hereditary Breast Cancer: Panel or Targeted Testing? Experience from a Clinical Cancer Genetics Practice.
    Doherty J; Bonadies DC; Matloff ET
    J Genet Couns; 2015 Aug; 24(4):683-7. PubMed ID: 25475920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The burden of pathogenic variants in clinically actionable genes in a founder population.
    Lynch MT; Maloney KA; Pollin TI; Streeten EA; Xu H; ; Shuldiner AR; Van Hout CV; Gonzaga-Jauregui C; Mitchell BD
    Am J Med Genet A; 2021 Nov; 185(11):3476-3484. PubMed ID: 34467620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
    Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Variant Findings and Challenges Associated With the Clinical Integration of Genomic Testing: An Interim Report of the Genomic Medicine for Ill Neonates and Infants (GEMINI) Study.
    Maron JL; Kingsmore SF; Wigby K; Chowdhury S; Dimmock D; Poindexter B; Suhrie K; Vockley J; Diacovo T; Gelb BD; Stroustrup A; Powell CM; Trembath A; Gallen M; Mullen TE; Tanpaiboon P; Reed D; Kurfiss A; Davis JM
    JAMA Pediatr; 2021 May; 175(5):e205906. PubMed ID: 33587123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Return of Actionable Variants Empirical (RAVE) Study, a Mayo Clinic Genomic Medicine Implementation Study: Design and Initial Results.
    Kullo IJ; Olson J; Fan X; Jose M; Safarova M; Radecki Breitkopf C; Winkler E; Kochan DC; Snipes S; Pacyna JE; Carney M; Chute CG; Gupta J; Jose S; Venner E; Murugan M; Jiang Y; Zordok M; Farwati M; Philogene M; Smith E; Shaibi GQ; Caraballo P; Freimuth R; Lindor NM; Sharp R; Thibodeau SN
    Mayo Clin Proc; 2018 Nov; 93(11):1600-1610. PubMed ID: 30392543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Web Platform vs In-Person Genetic Counselor for Return of Carrier Results From Exome Sequencing: A Randomized Clinical Trial.
    Biesecker BB; Lewis KL; Umstead KL; Johnston JJ; Turbitt E; Fishler KP; Patton JH; Miller IM; Heidlebaugh AR; Biesecker LG
    JAMA Intern Med; 2018 Mar; 178(3):338-346. PubMed ID: 29356820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interest in expanded carrier screening among individuals and couples in the general population: systematic review of the literature.
    Van Steijvoort E; Chokoshvili D; W Cannon J; Peeters H; Peeraer K; Matthijs G; Borry P
    Hum Reprod Update; 2020 Apr; 26(3):335-355. PubMed ID: 32099997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory.
    Punj S; Akkari Y; Huang J; Yang F; Creason A; Pak C; Potter A; Dorschner MO; Nickerson DA; Robertson PD; Jarvik GP; Amendola LM; Schleit J; Simpson DK; Rope AF; Reiss J; Kauffman T; Gilmore MJ; Himes P; Wilfond B; Goddard KAB; Richards CS
    Am J Hum Genet; 2018 Jun; 102(6):1078-1089. PubMed ID: 29754767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of large panel genetic evaluation of breast cancer patients in a community-based cancer institute.
    Bagwell AK; Sutton TL; Gardiner S; Johnson N
    Am J Surg; 2021 Jun; 221(6):1159-1163. PubMed ID: 33849710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cuban program for predictive testing of SCA2: 11 years and 768 individuals to learn from.
    Cruz-Mariño T; Velázquez-Pérez L; González-Zaldivar Y; Aguilera-Rodríguez R; Velázquez-Santos M; Vázquez-Mojena Y; Estupiñán-Rodríguez A; Laffita-Mesa JM; Reynaldo-Armiñán R; Almaguer-Mederos LE; Paneque M
    Clin Genet; 2013 Jun; 83(6):518-24. PubMed ID: 23495852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals.
    Stuckey A; Febbraro T; Laprise J; Wilbur JS; Lopes V; Robison K
    Am J Clin Oncol; 2016 Aug; 39(4):363-7. PubMed ID: 24710121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of SNP chips to detect rare pathogenic variants: retrospective, population based diagnostic evaluation.
    Mn W; L J; Jw H; Ks R; J T; At H; Cf W
    BMJ; 2021 Feb; 372():n214. PubMed ID: 33589468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting.
    DeFrancesco MS; Waldman RN; Pearlstone MM; Karanik D; Bernhisel R; Logan J; Alico L; Adkins RT
    Obstet Gynecol; 2018 Nov; 132(5):1121-1129. PubMed ID: 30303907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic testing: when to test, when to refer.
    Pagon RA
    Am Fam Physician; 2005 Jul; 72(1):33-4. PubMed ID: 16035680
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.